IP Library › Granted Patent US 12,453,734
Granted Patent B2
US 12,453,734 · App. 18/534,285 · Granted Oct 28, 2025

Modulators of rho-associated protein kinase

Inventors: Clifford D. Jones (Macclesfield, GB); Peter Bunyard (Macclesfield, GB); Gary Pitt (Macclesfield, GB); Liam Byrne (Macclesfield, GB); Thomas Pesnot (Chester, GB); Nicolas E. S. Guisot (Macclesfield, GB)
Assignee: Redx Pharma Limited
A61K31/538A61K31/4196A61K31/5377C07D403/12C07D403/14C07D405/14C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,453,734
App. No.
18/534,285
Granted
Oct 28, 2025
Kind
B2
Abstract

This invention relates to novel compounds and pharmaceutical compositions comprising. Compounds of the invention useful as modulators of Rho-associated protein kinase (ROCK), for example ROCK1 and/or ROCK2 inhibitors. Methods of treatment employing the compounds are also contemplated by the present invention. The compounds of the invention are useful in treating ROCK mediated diseases.

Claims (12)

1. A compound, wherein the compound is:

or a pharmaceutically acceptable salt thereof.

2. A compound, wherein the compound is:

3. A pharmaceutical composition, wherein the composition comprises the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

4. A pharmaceutical composition, wherein the composition comprises the compound of claim 2 , and a pharmaceutically acceptable adjuvant, diluent, or carrier.

5. A method of treating a condition selected from the group consisting of: fibrotic diseases, auto-immune, inflammatory-fibrotic conditions, inflammatory conditions, central nervous system disorders, and cancer, wherein the method comprises administering to a patient in need thereof a therapeutic amount of a compound which is:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein the condition is selected from the group consisting of: Idiopathic Pulmonary Fibrosis (IPF), systemic sclerosis (SSC), interstitial lung disease (ILD), type 1 diabetes, type 2 diabetes, diabetic nephropathy, Nonalcoholic Steatohepatitis (NASH), Nonalcoholic fatty liver disease (NAFLD), hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, peripheral circulatory disorder, peripheral artery occlusive disease, ischemia/reperfusion injury, pulmonary hypertension, angina, erectile dysfunction, fibroid lung, fibroid liver, fibroid kidney, glaucoma, ocular hypertension, retinopathy, rheumatoid arthritis, psoriasis, psoriatic arthritis, Sjogren's syndrome, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), SLE, cGVHD, inflammatory bowel disease, stenosis of the bowel, disorders involving neuronal degeneration or physical injury to neural tissue, Huntington's disease, Parkinson's Disease, Alzheimer's, Amyotrophic lateral sclerosis (ALS), multiple sclerosis, liver cancer, bladder cancer, hepatoma, squamous carcinoma of the lung, non-small cell lung cancer, adenocarcinoma of the lung, small-cell lung cancer, head and neck cancer, breast cancer, colon cancer, colorectal cancer, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, esophageal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, squamous cell cancer, pituitary cancer, astrocytoma, soft tissue sarcoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, brain cancer, endometrial cancer, testis cancer, cholangiocarcinoma, gallbladder carcinoma, gastric cancer and melanoma.

7. The method of claim 5 , wherein the condition is selected from the group consisting of: Sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Graves' disease, Addison's disease, Raynaud's phenomenon, or autoimmune hepatitis, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, degenerative arthritis, polymyalgia rheumatic, ankylosing spondylitis, reactive arthritis, gout, pseudogout, inflammatory joint disease, systemic lupus erythematosus, polymyositis, fibromyalgia, Achilles tendinitis, achondroplasia, acromegalic arthropathy, adhesive capsulitis, adult onset Still's disease, anserine bursitis, avascular necrosis, Behcet's syndrome, bicipital tendinitis, Blount's disease, brucellar spondylitis, bursitis, calcaneal bursitis, calcium pyrophosphate dihydrate deposition disease (CPPD), crystal deposition disease, Caplan's syndrome, carpal tunnel syndrome, chondrocalcinosis, chondromalacia patellae, chronic synovitis, chronic recurrent multifocal osteomyelitis, Churg-Strauss syndrome, Cogan's syndrome, corticosteroid-induced osteoporosis, costosternal syndrome, CREST syndrome, cryoglobulinemia, degenerative joint disease, dermatomyositis, diabetic finger sclerosis, diffuse idiopathic skeletal hyperostosis (DISH), discitis, discoid lupus erythematosus, drug-induced lupus, Duchenne's muscular dystrophy, Dupuytren's contracture, Ehlers-Danlos syndrome, enteropathic arthritis, epicondylitis, erosive inflammatory osteoarthritis, exercise-induced compartment syndrome, Fabry's disease, familial Mediterranean fever, Farber's lipogranulomatosis, Felty's syndrome, Fifth's disease, flat feet, foreign body synovitis, Freiberg's disease, fungal arthritis, Gaucher's disease, giant cell arteritis, gonococcal arthritis, Goodpasture's syndrome, granulomatous arteritis, hemarthrosis, hemochromatosis, Henoch-Schonlein purpura, Hepatitis B surface antigen disease, hip dysplasia, Hurler syndrome, hypermobility syndrome, hypersensitivity vasculitis, hypertrophic osteoarthropathy, immune complex disease, impingement syndrome, Jaccoud's arthropathy, juvenile ankylosing spondylitis, juvenile dermatomyositis, juvenile rheumatoid arthritis, Kawasaki disease, Kienbock's disease, Legg-Calve-Perthes disease, Lesch-Nyhan syndrome, linear scleroderma, lipoid dermatoarthritis, Lofgren's syndrome, Lyme disease, malignant synovioma, Marfan's syndrome, medial plica syndrome, metastatic carcinomatous arthritis, mixed connective tissue disease (MCTD), mixed cryoglobulinemia, mucopolysaccharidosis, multicentric reticulohistiocytosis, multiple epiphyseal dysplasia, mycoplasmal arthritis, myofascial pain syndrome, neonatal lupus, neuropathic arthropathy, nodular panniculitis, ochronosis, olecranon bursitis, Osgood-Schlatter's disease, osteoarthritis, osteochondromatosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteonecrosis, osteoporosis, overlap syndrome, pachydermoperiostosis Paget's disease of bone, palindromic rheumatism, patellofemoral pain syndrome, Pellegrini-Stieda syndrome, pigmented villonodular synovitis, piriformis syndrome, plantar fasciitis, polyarteritis nodosa, Polymyalgia rheumatic, polymyositis, popliteal cysts, posterior tibial tendinitis, Pott's disease, prepatellar bursitis, prosthetic joint infection, pseudoxanthoma elasticum, psoriatic arthritis, Raynaud's phenomenon, reactive arthritis/Reiter's syndrome, reflex sympathetic dystrophy syndrome, relapsing polychondritis, retrocalcaneal bursitis, rheumatic fever, rheumatoid vasculitis, rotator cuff tendinitis, sacroiliitis, salmonella osteomyelitis, sarcoidosis, saturnine gout, Scheuermann's osteochondritis, scleroderma, septic arthritis, seronegative arthritis, shigella arthritis, shoulder-hand syndrome, sickle cell arthropathy, Sjogren's syndrome, slipped capital femoral epiphysis, spinal stenosis, spondylolysis, staphylococcus arthritis, Stickler syndrome, subacute cutaneous lupus, Sweet's syndrome, Sydenham's chorea, syphilitic arthritis, systemic lupus erythematosus (SLE), Takayasu's arteritis, tarsal tunnel syndrome, tennis elbow, Tietze's syndrome, transient osteoporosis, traumatic arthritis, trochanteric bursitis, tuberculosis arthritis, arthritis of Ulcerative colitis, undifferentiated connective tissue syndrome (UCTS), urticarial vasculitis, viral arthritis, Wegener's granulomatosis, Whipple's disease, Wilson's disease, yersinial arthritis, atherosclerosis, rheumatoid arthritis (RA), hemangiomas, angiofibromas, psoriasis, Other non limiting retinopathy of prematurity (retrolental fibroplasia), corneal graft rejection, corneal neovascularization related to complications of refractive surgery, corneal neovascularization related to contact lens complications, corneal neovascularization related to pterygium, recurrent pterygium, corneal ulcer disease, non-specific ocular surface disease, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Crohn's disease, autoimmune nephritis, primary biliary cirrhosis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis, delayed hypersensitivity reactions, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, cognition defects induced by neuronal inflammation, Osier-Weber syndrome, restenosis, fungal infections, parasitic infections, and viral infections.

8. A method of treating a condition selected from the group consisting of: fibrotic diseases, auto-immune, inflammatory-fibrotic conditions, inflammatory conditions, central nervous system disorders, and cancer, wherein the method comprises administering to a patient in need thereof a therapeutic amount of a compound which is:

9. The method of claim 8 , wherein the condition is selected from the group consisting of: Idiopathic Pulmonary Fibrosis (IPF), systemic sclerosis (SSC), interstitial lung disease (ILD), type 1 diabetes, type 2 diabetes, diabetic nephropathy, Nonalcoholic Steatohepatitis (NASH), Nonalcoholic fatty liver disease (NAFLD), hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, peripheral circulatory disorder, peripheral artery occlusive disease, ischemia/reperfusion injury, pulmonary hypertension, angina, erectile dysfunction, fibroid lung, fibroid liver, fibroid kidney, glaucoma, ocular hypertension, retinopathy, rheumatoid arthritis, psoriasis, psoriatic arthritis, Sjogren's syndrome, asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease (COPD), SLE, cGVHD, inflammatory bowel disease, stenosis of the bowel, disorders involving neuronal degeneration or physical injury to neural tissue, Huntington's disease, Parkinson's Disease, Alzheimer's, Amyotrophic lateral sclerosis (ALS), multiple sclerosis, liver cancer, bladder cancer, hepatoma, squamous carcinoma of the lung, non-small cell lung cancer, adenocarcinoma of the lung, small-cell lung cancer, head and neck cancer, breast cancer, colon cancer, colorectal cancer, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, esophageal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, squamous cell cancer, pituitary cancer, astrocytoma, soft tissue sarcoma, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, brain cancer, endometrial cancer, testis cancer, cholangiocarcinoma, gallbladder carcinoma, gastric cancer and melanoma.

10. The method of claim 8 , wherein the condition is selected from the group consisting of: Sarcoidosis, sclerosis, primary biliary sclerosis, sclerosing cholangitis, dermatitis, atopic dermatitis, Still's disease, chronic obstructive pulmonary disease, Guillain-Barre disease, Graves' disease, Addison's disease, Raynaud's phenomenon, or autoimmune hepatitis, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, degenerative arthritis, polymyalgia rheumatic, ankylosing spondylitis, reactive arthritis, gout, pseudogout, inflammatory joint disease, systemic lupus erythematosus, polymyositis, fibromyalgia, Achilles tendinitis, achondroplasia, acromegalic arthropathy, adhesive capsulitis, adult onset Still's disease, anserine bursitis, avascular necrosis, Behcet's syndrome, bicipital tendinitis, Blount's disease, brucellar spondylitis, bursitis, calcaneal bursitis, calcium pyrophosphate dihydrate deposition disease (CPPD), crystal deposition disease, Caplan's syndrome, carpal tunnel syndrome, chondrocalcinosis, chondromalacia patellae, chronic synovitis, chronic recurrent multifocal osteomyelitis, Churg-Strauss syndrome, Cogan's syndrome, corticosteroid-induced osteoporosis, costosternal syndrome, CREST syndrome, cryoglobulinemia, degenerative joint disease, dermatomyositis, diabetic finger sclerosis, diffuse idiopathic skeletal hyperostosis (DISH), discitis, discoid lupus erythematosus, drug-induced lupus, Duchenne's muscular dystrophy, Dupuytren's contracture, Ehlers-Danlos syndrome, enteropathic arthritis, epicondylitis, erosive inflammatory osteoarthritis, exercise-induced compartment syndrome, Fabry's disease, familial Mediterranean fever, Farber's lipogranulomatosis, Felty's syndrome, Fifth's disease, flat feet, foreign body synovitis, Freiberg's disease, fungal arthritis, Gaucher's disease, giant cell arteritis, gonococcal arthritis, Goodpasture's syndrome, granulomatous arteritis, hemarthrosis, hemochromatosis, Henoch-Schonlein purpura, Hepatitis B surface antigen disease, hip dysplasia, Hurler syndrome, hypermobility syndrome, hypersensitivity vasculitis, hypertrophic osteoarthropathy, immune complex disease, impingement syndrome, Jaccoud's arthropathy, juvenile ankylosing spondylitis, juvenile dermatomyositis, juvenile rheumatoid arthritis, Kawasaki disease, Kienbock's disease, Legg-Calve-Perthes disease, Lesch-Nyhan syndrome, linear scleroderma, lipoid dermatoarthritis, Lofgren's syndrome, Lyme disease, malignant synovioma, Marfan's syndrome, medial plica syndrome, metastatic carcinomatous arthritis, mixed connective tissue disease (MCTD), mixed cryoglobulinemia, mucopolysaccharidosis, multicentric reticulohistiocytosis, multiple epiphyseal dysplasia, mycoplasmal arthritis, myofascial pain syndrome, neonatal lupus, neuropathic arthropathy, nodular panniculitis, ochronosis, olecranon bursitis, Osgood-Schlatter's disease, osteoarthritis, osteochondromatosis, osteogenesis imperfecta, osteomalacia, osteomyelitis, osteonecrosis, osteoporosis, overlap syndrome, pachydermoperiostosis Paget's disease of bone, palindromic rheumatism, patellofemoral pain syndrome, Pellegrini-Stieda syndrome, pigmented villonodular synovitis, piriformis syndrome, plantar fasciitis, polyarteritis nodosa, Polymyalgia rheumatic, polymyositis, popliteal cysts, posterior tibial tendinitis, Pott's disease, prepatellar bursitis, prosthetic joint infection, pseudoxanthoma elasticum, psoriatic arthritis, Raynaud's phenomenon, reactive arthritis/Reiter's syndrome, reflex sympathetic dystrophy syndrome, relapsing polychondritis, retrocalcaneal bursitis, rheumatic fever, rheumatoid vasculitis, rotator cuff tendinitis, sacroiliitis, salmonella osteomyelitis, sarcoidosis, saturnine gout, Scheuermann's osteochondritis, scleroderma, septic arthritis, seronegative arthritis, shigella arthritis, shoulder-hand syndrome, sickle cell arthropathy, Sjogren's syndrome, slipped capital femoral epiphysis, spinal stenosis, spondylolysis, staphylococcus arthritis, Stickler syndrome, subacute cutaneous lupus, Sweet's syndrome, Sydenham's chorea, syphilitic arthritis, systemic lupus erythematosus (SLE), Takayasu's arteritis, tarsal tunnel syndrome, tennis elbow, Tietze's syndrome, transient osteoporosis, traumatic arthritis, trochanteric bursitis, tuberculosis arthritis, arthritis of Ulcerative colitis, undifferentiated connective tissue syndrome (UCTS), urticarial vasculitis, viral arthritis, Wegener's granulomatosis, Whipple's disease, Wilson's disease, yersinial arthritis, atherosclerosis, rheumatoid arthritis (RA), hemangiomas, angiofibromas, psoriasis, retinopathy of prematurity (retrolental fibroplasia), corneal graft rejection, corneal neovascularization related to complications of refractive surgery, corneal neovascularization related to contact lens complications, corneal neovascularization related to pterygium, recurrent pterygium, corneal ulcer disease, non-specific ocular surface disease, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, Crohn's disease, autoimmune nephritis, primary biliary cirrhosis, acute pancreatitis, allograph rejection, allergic inflammation, contact dermatitis, delayed hypersensitivity reactions, inflammatory bowel disease, septic shock, osteoporosis, osteoarthritis, cognition defects induced by neuronal inflammation, Osier-Weber syndrome, restenosis, fungal infections, parasitic infections, and viral infections.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2025
From: REDX PHARMA PLC
To: REDX PHARMA LIMITED
Reel/Frame 071481/0876 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2023
From: JONES, CLIFFORD D.; BUNYARD, PETER; PITT, GARY; BYRNE, LIAM; PESNOT, THOMAS; GUISOT, NICOLAS E.S.
To: REDX PHARMA PLC
Reel/Frame 065861/0166 →
Priority Claims (1)
GB 1801226 · Jan 25, 2018 · national
Continuity (3)
Continuation 17896626 · Aug 26, 2022
Continuation 16964904
Related Publication 20240216386A1 · Jul 4, 2024
References Cited (44)
US 7951820B2 · Bebbington et al. · 2011 [cited by applicant]
US 11497751B2 · Jones et al. · 2022 [cited by applicant]
US 11878020B2 · Jones et al. · 2024 [cited by applicant]
US 20030055044A1 · Davies et al. · 2003 [cited by applicant]
US 20040214817A1 · Pierce et al. · 2004 [cited by applicant]
US 20050288347A1 · Hodge et al. · 2005 [cited by applicant]
US 20110082136A1 · Machacek et al. · 2011 [cited by applicant]
US 20110190355A1 · Klein et al. · 2011 [cited by applicant]
US 20130123284A1 · Arnold et al. · 2013 [cited by applicant]
US 20190002442A1 · Zhao et al. · 2019 [cited by applicant]
US 20210038606A1 · Jones et al. · 2021 [cited by applicant]
US 20230021916A1 · Jones et al. · 2023 [cited by applicant]
US 20250122173A1 · Guisot et al. · 2025 [cited by applicant]
WO WO199320066A1 · 1993 [cited by applicant]
WO WO2004046120A2 · 2004 [cited by applicant]
WO WO2004052280A2 · 2004 [cited by applicant]
WO WO2005013982A1 · 2005 [cited by applicant]
WO WO2006135383A2 · 2006 [cited by applicant]
WO WO2007139967A2 · 2007 [cited by applicant]
WO WO2012045883A1 · 2012 [cited by applicant]
WO WO2012084704A1 · 2012 [cited by applicant]
WO WO2013133367A1 · 2013 [cited by applicant]
WO WO2015054317A1 · 2015 [cited by applicant]
WO WO2016138335A1 · 2016 [cited by applicant]
WO WO2016138336A1 · 2016 [cited by applicant]
WO WO2019000682A1 · 2019 [cited by applicant]
WO WO2019001572A1 · 2019 [cited by applicant]
WO WO2019145729A1 · 2019 [cited by applicant]
WO WO2019210008A1 · 2019 [cited by applicant]
WO WO2022169946A1 · 2022 [cited by applicant]
Great Britain Search Report for Application No. GB2200735.5 dated Jun. 1, 2022. [cited by applicant]
Aurelio et al., “From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl) thiazol-2-yl)amino)phenol … [cited by applicant]
CA Office Action translation for CN 201980010083.3 dated Nov. 10, 2022. [cited by applicant]
Chinese Office Action for CN Application No. 201980010083.3 dated Nov. 10, 2022. [cited by applicant]
Defert et al., “Rho kinase inhibitors: a patent review (2014-2016),” Expert Opin Ther Pat, 27(4): 507-515 (2017). [cited by applicant]
Dhar et al., “A Survey of Cyclic Replacements for the Central Diamide Moiety of Inhibitors of Inosine Monophosphate Dehydrogenase,” Bioorg Med Chem, 12: 3125-3128 (2002). [cited by applicant]
El-Sherief et al., “Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking and mechanistic studies,” Biorg Chem, 76: 314-325 (2018). [cited by applicant]
Great Britain Search Report for Application No. GB1801226.0 dated Oct. 11, 2018. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/GB2019/050215 dated Mar. 6, 2019. [cited by applicant]
Loirand, “Rho Kinases in Health and Disease: From Basic Science to translational Research,” Pharmacol Rev, 67: 1074-1095 (2015). [cited by applicant]
Masakatsu Nozaki et al., Pharmaceutical Chemistry, first edition, Kagaku-Dojin Publishing Company, Inc, 1995, pp. 98-99. [cited by applicant]
Okawa et al., “Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure,” J Med Chem, 60: 6942-6990 (2017). [cited by applicant]
Chinese Office Action for CN Application No. 2023-200631 dated Oct. 22, 2024. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/GB23/50109 dated Jul. 23, 2024. [cited by applicant]